pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
168
stories
22d
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
23d
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
23d
Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn
stat
23d
Claris collects $118M to take eye drop into pivotal testing next year
endpoints
23d
An eye drug biotech banks $118M and stocks its executive suite
biopharma dive
23d
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
globenewswire health
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
24d
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
fiercebiotech
24d
Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill
endpoints
24d
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
biospace
24d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
24d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
24d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
24d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
25d
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
25d
FDA has recommitted to adcomms—but to what end?
biospace
28d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
29d
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
29d
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
29d
Job dissatisfaction and health care access uncertainty grows in the U.S., new study finds
stat
Jul 22, 26
STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027
stat
Jul 22, 26
As Maui recovers from devastating fires, a study offers vision for new rural health model
stat
Jul 21, 26
Opinion: Pete Hegseth, ‘The Odyssey,’ and the testosterone myth
stat
Jul 21, 26
Is there an exodus underway at Epic?
stat
Jul 21, 26
THC drinks are sold beside sodas, iced tea, and even chocolate milk, often in violation of state laws
stat
Jul 21, 26
Roche taps Foundation Medicine’s chief as new North America Diagnostics lead, creates new commercial role
fiercebiotech
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jul 20, 26
BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
← prev
page 3 of 6
next →
